Candonilimab is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Rui-hua Xu, MD, PhD (1), Shanghai Zhongshan Hospital (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1). Registered phase: Phase 2. Conditions studied include Esophageal Squamous Cell Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Soft Tissue Sarcoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05926700 | Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (ClinicalTrials.gov ↗) Soft Tissue Sarcoma |
Phase 2 | Recruiting |
| NCT06587425 | The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Gastric or Gastroesophageal Junction Adenocarcinoma |
Phase 2 | Recruiting |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Esophageal Squamous Cell Carcinoma | 1 |
| Gastric or Gastroesophageal Junction Adenocarcinoma | 1 |
| Soft Tissue Sarcoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Rui-hua Xu, MD, PhD | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Register | Candonilimab trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Candonilimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Candonilimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.